Clinical Trial Update: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 open-label trial assessing safety and efficacy of replacement factor VIII (rFVIIIFc) in previously untreated males with severe Hemophilia A; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rFVIIIFc (recombinant factor VIII Fc fusion protein)

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2020-08-13